Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: Ministry of Health DRC; Chart: Andrew Witherspoon/Axios

The Democratic Republic of the Congo started using an experimental vaccine against the deadly Ebola virus yesterday after identifying it as the virulent Zaire strain. The latest outbreak has spread to a conflict region and is suspected of killing at least 36 people during its first week.

Why it matters: Testing and approving an Ebola vaccine is a priority for global health officials as further outbreaks are expected — and the U.S. hopes to get the Food and Drug Administration to consider approval for a vaccine in 18 months or so.

"As I said before in May [during prior DRC Ebola outbreak], 'It's not over yet, folks, because this is going to come back.'"
— Anthony Fauci, director, National Institute of Allergy and Infectious Diseases

Background: Out of the four Ebola strains that humans can catch, the Zaire strain currently in DRC is the deadliest — but it's also one targeted by most of the vaccines and treatments, Fauci tells Axios. The DRC and surrounding countries often have outbreaks because they have a "reservoir" of infected bats and non-human primates that can transmit the disease to humans — "so this is not a fluke," Fauci says.

Driving the news: DRC officials now are vaccinating with 3,220 doses of the experimental rVSV-ZEBOV vaccine, wielding it as a ring vaccine where the circle of people in contact with the infected are vaccinated as well. They have requested more.

This is the 10th such outbreak in the country since 1976, but the positive side of this is that "they are pretty good at knowing how to deal with Ebola," Fauci says.

However, there are challenges that health workers have not had to deal with in other outbreaks, namely that the border region between the DRC, Uganda and Rwanda is home to active rebel groups, about 1 million displaced people and the largest UN peacekeeping force in the world.

"The real disturbing aspect is that it is now in a [conflict] zone... it's difficult to get health care workers in and it's dangerous because there are people who are terrorists who target health care workers often," Fauci says.

Hope for the future: Nevertheless, there are several promising vaccines and therapies out there — all of them experimental right now, he says.

  • While DRC health officials were unable to comment by publication, Fauci says he hopes the authorities decide to conduct a protocol-driven, randomized trial without a placebo to help gather more information on the different vaccines or treatments.

Current experimental treatments, some of which may be tried in DRC, include:

1.Vaccines: Two promising ones are rVSV-ZEBOV and Ad26.ZEBOV with a MVA‐BN‐Filo boost. Both of these are currently undergoing testing for safety and its ability to generate a response from the immune system, as well as other factors.

  • The rVSV-ZEBOV vaccine, which is currently being used in DRC, could possibly be considered for FDA approval starting in 18 months, depending on the trials and the regulator itself, Fauci says.
  • The Ad26.ZEBOV with a MVA‐BN‐Filo boost is being evaluated in two large trials.

2. Other treatments: ZMapp and mAb114 are antibodies designed to protect the body against the virus. Favipiravir and remdesivir (GS-5734) are anti-viral agents currently used against other viruses that are now being studied for their efficacy against Ebola.

Editor's note: This piece was corrected to take out the cAd3-EBOZ vaccine and the anti-viral brincidofovir (which are in small studies), and to add in Ad26.ZEBOV and remdesivir .

Go deeper

Updated 32 mins ago - Politics & Policy

Giuliani associate Lev Parnas convicted of campaign finance crimes

Lev Parnas, a former associate of then-President Donald Trump’s personal lawyer Rudy Giuliani. Photo: Stefani Reynolds/Bloomberg via Getty Images

Florida businessman Lev Parnas was convicted Friday on charges of conspiracy to make foreign contributions to political campaigns, according to multiple outlets.

Why it matters: Prosecutors said Parnas, then an associate of former President Donald Trump's personal lawyer Rudy Giuliani, funneled over $150,000 from a Russian businessman into U.S. campaigns as part of an effort to land licenses in the U.S.'s legal cannabis industry.

Supreme Court agrees to hear challenges to Texas abortion law

Photo: Saul Loeb/AFP via Getty Images

The Supreme Court on Friday agreed to hear two cases challenging Texas' abortion law, which bans the procedure as soon as six weeks into pregnancy, but left the law in place in the meantime.

Why it matters: The court is moving extraordinarily fast on the Texas cases, compressing into just a few days a process that normally takes months. And that schedule means the court will take up Texas' ban a month before it hears another major abortion case — a challenge to Mississippi's own 2018 ban on abortions after 15 weeks.

Officials warn 5 key tech sectors will determine whether China overtakes U.S.

Illustration: Aïda Amer/Axios

U.S. intelligence officials responsible for protecting advanced technologies have narrowed their focus to five key sectors: artificial intelligence, quantum computing, biotechnology, semiconductors and autonomous systems.

Why it matters: China and Russia are employing a variety of legal and illegal methods to undermine and overtake U.S. dominance in these critical industries, officials warned in a new paper. Their success will determine "whether America remains the world’s leading superpower or is eclipsed by strategic competitors."